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proper selection of beam orientations. With intensity 
modulated radiotherapy (IMRT) highly conformal dose 
distribution can be achieved, but volumes irradiated by low 
doses can be larger than with 3D-CRT. Regarding the dose to 
OARs, with multicatheter BT the critical structures can be 
better spared than with 3D-CRT/IMRT except for the heart 
whose dose in BT is strongly dependent on the location of the 
PTV. With image guidance in EBRT the dose to OARs can be 
significantly reduced. At left sided lesion the dose to heart 
can be considerably decreased with deep inspiration breath-
hold technique. 
With special EBRT equipments such as Cyberknife or 
Tomotherapy which are equipped with image guidance 
smaller CTV-PTV margin can applied which reduces the dose 
to OARs while maintaining proper target coverage. Real-time 
tracking with Cyberknife can provide better target volume 
coverage and spare nearby critical organs, but the treatment 
time is too long.  
Proton beam irradiation, due to the more favourable dose 
characteristics of proton beam, can provide the less dose to 
organs at risk, but the availability of the technique is sparse.  
 





Evaluating the impact of clinical uncertainties on 
TCP/NTCP models in brachytherapy 
N. Nesvacil
1Medical University of Vienna, Department of Radiotherapy- 
Comprehensive Cancer Center- and CDL for Medical 
Radiation Research, Vienna, Austria 
1, K. Tanderup2, C. Kirisits1 
2Aarhus University Hospital, Department of Oncology, 
Aarhus, Denmark 
 
During the past decade many investigations have been 
performed to investigate and minimize clinical uncertainties 
that could lead to significant deviations between the planned 
and the delivered doses in radiotherapy. Among the sources 
of uncertainties patient setup plays an important role in 
EBRT. Analogously, in brachytherapy the geometric 
uncertainties caused by movement or reconstruction 
uncertainties of the implant position in relation to the CTV 
and/or normal tissue can lead to systematic or random 
variations between prescribed and delivered dose. At the 
same time interfraction or intrafraction variations of the 
anatomy, e.g. caused by variations of position, shape and 
filling status of OARs, during the course of a treatment pose 
an additional challenge to all types of radiotherapy. 
Recent investigations of different types of uncertainties for a 
variety of treatment sites, including gynaecological, 
prostate, head and neck, or breast BT, have led to numerous 
reports on accuracy of image guided brachytherapy. These 
have triggered the development of the recommendations for 
reporting uncertainties in terms of their dosimetric impact 
(GEC-ESTRO / AAPM guidelines, Kirisits et al. 2014, Radiother 
Oncol 110). Following these guidelines for uncertainty 
analysis, individual BT workflows can be analysed in order to 
identify those components of the overall uncertainty budget 
which will have the largest impact on the total delivered 
treatment dose. Once identified, strategies for reducing 
these uncertainties can be taken into consideration, such as 
repetitive/near treatment imaging, advanced online dose 
verification tools, etc.  
In order to assess the clinical benefit of such uncertainty 
reduction measures, it is important to understand the 
interplay between different types of uncertainties and their 
combined effect on clinical outcome, in terms of TCP and 
NTCP. In the past, dose-response relationships have been 
derived from clinical data, which could not take into account 
the accuracy of the reported dose. For some treatment sites, 
e.g. for cervical cancer, uncertainty budgets and dose-
response relations have been described in the literature in 
sufficient detail that now allows us to simulate what impact 
specific clinical uncertainties would have on TCP/NTCP 
modelling. In addition to that, one can simulate how TCP or 
NTCP models would change, if systematic and random 
dosimetric uncertainties could be reduced.  
In this presentation a few such simulation examples will be 
shown to illustrate the clinical impact of uncertainties for 
source calibration, applicator reconstruction, interobserver 
variations and anatomical interfraction variations. Strategies 
for reducing clinical uncertainties will be discussed.  
Finally, we will come one step closer to answering the 
questions whether reducing our clinical uncertainties is 
possible and meaningful, and if so, which strategies would 
have the largest clinical impact. In the future dose 
prescription may be affected by technological improvements 
that lead to a reduction of dosimetric uncertainties and a 
subsequent widening of the therapeutic window. These 
developments would benefit from a common effort in the BT 
community to investigate dose-response relationships for 
various treatment sites, and to simultaneously report 
uncertainty budgets for the underlying workflows applied for 
image guided brachytherapy, in our current clinical practice.  
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The probability of local tumor control is limited by the 
amount of dose deliverable to the tumor, which is limited by 
the amount of radiation induced toxicity. There is a large, 
and currently unpredictable, interpatient variation in the 
amount of observed toxicity. Since the expected patient 
specific toxicity is not known, the prescribed dose is 
restricted such that, within the patient population, the 
number of patients with major or even fatale toxicity is 
limited. Due to the interpatient variation in toxicity the 
population based dose limits lead to undertreatment of 
patients with low normal tissue irradiation sensitivity. This 
issue could be addressed if, on a patient specific level, it 
would be possible to classify the patients according to 
expected toxicity prior to or early during the treatment 
course – which calls for predictive models of toxicity.  
Many clinical factors such as performance status, patient 
age, and other co-morbidity are associated with observed 
toxicity, and models based on such factors are today 
available (e.g. http://www.predictcancer.org/). The models 
can be a useful tool to optimize the treatment on the 
population level, but in order to be used on a patient specific 
level, input of more patient specific information is needed. 
During planning and delivery of radiotherapy a large number 
of patient images are acquired. The information content in 
the images is often reduced to a few figures (e.g. volume of 
tumor or measurement of patient positioning). The different 
types of images (CT/SPECT/PET/MR/CBCT) are available for 
free, and it is tempting to believe that these images could 
provide more patient specific information, if extracted in a 
proper way. Also as part of the response evaluation it is likely 
that imaging could be used to quantify the degree of toxicity. 
At the end of the day, the overall toxicity level can only be 
assessed by the patient, who should cope with the toxicity on 
a daily basis. However, in terms of biological tissue response 
to the radiation, patient (or oncologist) reported toxicity is 
likely to underestimate the “true” amount of toxicity since 
the toxicity effects might be overshadowed by treatment 
related gains e.g. re-ventilation of obstructed airways due to 
tumor regression in lung cancer patients, or because the 
toxicity is assumed to be related to co-morbidity. 
Disentanglement of such effects is desirable during creation 
of predictive models of toxicity; which might be feasible by 
evaluation of follow-up images.  
The most used imaging-based feature to predict toxicity is 
obviously measurement of dose to individual risk organs (e.g. 
dose to heart or lung). These values are routinely used 
clinically and typical not regarded as image-based features. 
More advanced imaging-based features such as homogeneity, 
texture, or time changes of signals/images has been proposed 
